@misc{10481/58724,
year = {2019},
month = {11},
url = {http://hdl.handle.net/10481/58724},
abstract = {Background: The prognosis of early stage non-small cell lung cancer (NSCLC) is quite
disappointing and the benefits of adjuvant therapy are relatively small. Thus, there is an urgent
need to identify novel prognostic and predictive biomarkers. Lung adenocarcinoma has distinct
clinical–pathological characteristics and novel therapeutic strategies are under active evaluation
in the adjuvant setting. Here, we investigated the prognostic impact of circulating tumor cells
(CTCs) and gene and miRNA tissue expression in resectable NSCLC. Results: ADC (n = 47) and SCC (n = 50) revealed
different tissue expression profiles, resulting in the presence of different CTC subpopulations. In ADC,
miR-155 correlated with AXL and IL6R expression, which were related to the presence of EMT CTC1
(p = 0.014 and p = 0.004). In the multivariate analysis, CTC2 was an independent prognostic factor
for relapse-free survival, and CTC3 and AXL were independent prognostic for overall survival only
in ADC. Neither the surgery nor the adjuvant treatment influenced the prognosis of these patients.
Conclusions: Our study elucidate the prognostic impact of tissue AXL expression and the presence of
CTCs after surgery in adenocarcinoma patients. Tissue AXL expression and CTC EMT activation
could potentially represent biomarkers for the stratification of ADC patients that might benefit from
new adjuvant therapies.},
organization = {This work was supported by the Department of Health and SocialWelfare of the Regional Government of
Andalusia [PI-0294-2012] and Diego de Miguel Perez was supported by the PhD (2014) and the PhD International
Mobility (2019) grants from the University of Granada, Spain.},
publisher = {MDPI},
keywords = {Circulating tumor cells},
keywords = {Adenocarcinoma},
keywords = {Liquid biopsy},
keywords = {NSCLC},
keywords = {AXL},
keywords = {Prognosis},
title = {Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma},
doi = {10.3390/cancers11111750},
author = {Miguel-Pérez, Diego de and Bayarri Lara, Clara Isabel and Ortega, Francisco G. and Russo, Alessandro and Moyano Rodríguez, María José and Álvarez Cubero, María Jesús and Maza Serrano, Elizabeth and Lorente Acosta, José Antonio and Rolfo, Christian and Serrano, María José},
}